KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Share-based Compensation: 2009-2025

Historic Share-based Compensation for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to $10.3 million.

  • Neogenomics' Share-based Compensation was N/A to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.6 million, marking a year-over-year change of. This contributed to the annual value of $33.4 million for FY2024, which is 35.64% up from last year.
  • According to the latest figures from Q3 2025, Neogenomics' Share-based Compensation is $10.3 million, which was down 15.62% from $12.2 million recorded in Q2 2025.
  • In the past 5 years, Neogenomics' Share-based Compensation registered a high of $12.2 million during Q2 2025, and its lowest value of $2.7 million during Q1 2021.
  • Moreover, its 3-year median value for Share-based Compensation was $8.3 million (2024), whereas its average is $8.4 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first surged by 356.20% in 2022, then plummeted by 60.69% in 2023.
  • Quarterly analysis of 5 years shows Neogenomics' Share-based Compensation stood at $10.1 million in 2021, then plummeted by 53.66% to $4.7 million in 2022, then skyrocketed by 49.90% to $7.0 million in 2023, then increased by 19.14% to $8.3 million in 2024, then surged by 38.15% to $10.3 million in 2025.
  • Its last three reported values are $10.3 million in Q3 2025, $12.2 million for Q2 2025, and $10.8 million during Q1 2025.